carvedilol


Also found in: Dictionary, Thesaurus, Wikipedia.
Related to carvedilol: Ramipril

carvedilol

 [kahr´vĕ-dil″ol]
a beta-adrenergic blocking agent used in treatment of hypertension and as an adjunct in treatment of congestive heart failure; administered orally.

car·ve·di·lol

(kar-vē'dil-ol),
An antihypertensive and antianginal agent, also used in congestive heart failure.

carvedilol

/car·ve·dil·ol/ (kahr´vĕ-dil″ol) a beta-adrenergic blocking agent used in the treatment of hypertension and as an adjunct in the treatment of congestive heart failure.

carvedilol

(kär-vā′dĭ-lôl′, -lōl′ -vĕd′ĭ-)
n.
A beta-blocker drug, C24H26N2O4, used especially to treat congestive heart failure and hypertension.

carvedilol

an alpha-/beta-adrenergic blocker.
indications It is used to treat congestive heart failure and essential hypertension, either alone or in combination with other antihypertensives.
contraindications Known hypersensitivity to this drug, bronchial asthma, class IV decompensated cardiac failure, second- or third-degree heart block, cardiogenic shock, or severe bradycardia and pulmonary edema prohibits the use of carvedilol.
adverse effects Life-threatening effects of this drug include atrioventricular block, bradycardia, congestive heart failure, pulmonary edema, and thrombocytopenia. Other serious adverse effects include somnolence, depression, ataxia, diarrhea, dependent edema, peripheral edema, extrasystoles, hypertension, hypotension, palpitations, peripheral ischemia, urinary tract infection, viral infection, and hypertriglyceridemia.

carvedilol

A drug used in the treatment of HEART FAILURE and ANGINA PECTORIS. A brand name is Eucardic.

carvedilol (kär´vədil´ol),

n brand name: Coreg;
drug class: nonselective β-adrenergic blocking agent with α-blocking activity;
action: produces fall in blood pressure without reflex tachycardia or significant reduction in heart rate;
use: essential hypertension alone or with other antihypertensives.

carvedilol

a third generation beta-adrenergic blocker used in the treatment of congestive heart failure.
References in periodicals archive ?
Unadjusted findings showed that the patients treated with atenolol consistently fared better than did those treated with either carvedilol or metoprolol tartrate for both heart failure hospitalizations and for hospitalizations plus deaths.
Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group.
Patients were randomized to variceal band ligation performed twice weekly until eradication (77 patients) or to carvedilol at 6.
GlaxoSmithKline (GSK) markets carvedilol in the United States under the brand name Coreg.
In contrast, the GEMINI study results showed that carvedilol effectively lowered blood pressure while having a neutral impact on blood-sugar levels, lipids and weight gain.
Food & Drug Administration to market Carvedilol tablets in the U.
Carvedilol is an alpha/beta-adrenergic blocking agent indicated for the treatment of left ventricular dysfunction following myocardial infarction in clinically stable patients, and hypertension.
Carvedilol is indicated for the treatment of mild-to-severe heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitor and digitalis.
Ibuprofen (most widely used analgesic and anti-inflammatory drug), Fenofibrate (the most common drug to lower cholesterol and triglycerides), Repaglinide (of Meglitinides drugs group recently used for diabetes treatment), Azithromycin (effective drug for treatment of respiratory infections, uterine and middle ear), Carvedilol (a drug for the treatment of heart failure, ischemia) and Aprepitant (used to prevent nausea and vomiting that may occur within 24 hours after receiving cancer chemotherapy treatment) have been produced in laboratory scale and semi-industrial scale," Mehrdad Hamidi, a nanodrugs professor, told FNA on Saturday.
You can check related of Europe Carvedilol Industry 2015 Market Research Report
One such medicine was Carvedilol, now under clinical investigation in Alzheimer 's disease with the intent to slow down memory deterioration.
and his colleagues conducted a systematic review and meta-analysis comparing outcomes between clinical trial subjects with systolic HF or AMI receiving carvedilol and those receiving betarselective BBs (specifically atenolol, metoprolol, bisoprolol, and nebivolol) (Am.